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Available online 13 June 2019Background:Whether continuous positive airway pressure (CPAP) treatment can improve depression or anxiety
symptoms in obstructive sleep apnoea (OSA) patients remains uncertain.
Methods: Secondary analysis of the Sleep Apnea Cardiovascular Endpoints (SAVE) trial, combinedwith a system-
atic review of randomised evidence. The SAVE secondary analyses involved 2410 patients with co-existing
moderate–severe OSA and established cardiovascular disease randomly allocated to CPAP treatment plus usual
care or usual care alone and followed up for 3·7 (SD 1·6) years. We evaluated the effect of CPAP treatment on
depression and anxiety caseness (scores ≥8 on theHospital Anxiety and Depression Scale depression and anxiety
subscales [HADS-D and HADS-A]) for OSA patients.
Findings: CPAP treatment was associated with reduced odds of depression caseness (adjusted odds ratio [OR]
0·80, 95% confidence interval [CI] 0·65–0·98, P= 0·031) compared to usual care in the SAVE trial and the treat-
ment effect was greater in those with pre-existing depression symptoms. A systematic review of 20 randomised
trials including 4255 participants confirmed a benefit of CPAP in reducing depression symptoms in OSA patients:Keywords:
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90 D. Zheng et al. / EClinicalMedicine 11 (2019) 89–96the overall effect (standardisedmean difference) was−0·18 (95% CI−0·24 to−0·12). No effect of CPAP treat-
ment on anxiety caseness was found both in patients of the SAVE study (adjusted OR 0·98, 95% CI 0·78–1·24, P
= 0·89) and the systematic review.
Interpretation: CPAP reduces depression symptoms in patients with co-existing OSA and CVD independently of
improvements in sleepiness.© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. IntroductionDepression and anxiety are public health challenges worldwide,
contributing an enormous amount of humanmisery and lost health. De-
pression and anxiety commonly affect patients with chronic conditions,
such as obstructive sleep apnoea (OSA) and cardiovascular (CV) disease,
and they adversely impact on prognosis, quality of life and treatment
adherence [1–5]. The relationship between abnormal mood and OSA
is complex and bidirectional, with various potential pathophysiological
mechanisms including sleep fragmentation, hypoxia, oxidative stress,
inflammation and neurotransmitter imbalance [6,7]. While continuous
positive airway pressure (CPAP), the most widely used treatment for
OSA, improves subjective symptoms such as daytime sleepiness, the ef-
fects specifically on depression and anxiety are uncertain. Two recent
systematic reviews of randomised trials on the effect of CPAP on depres-
sion and anxiety reported conflicting conclusions [8,9]. Existingfindings
are variable across studies due, in part, to different study designs, small
patient numbers, short periods of follow-up, and from an emphasis on
depression over anxiety patterns of abnormal mood [10–24].
The internationalmulticenter Sleep Apnea Cardiovascular Endpoints
(SAVE) study assessed the effectiveness of CPAP treatment for the pre-
vention of serious CV events in 2717 patients with co-existing OSA
and coronary and/or cerebrovascular CV disease. A secondary aim was
to determinewhether CPAP reduced depression and anxiety symptoms,
and statistically significant reductions were apparent at the end-of-
study visit after several years of treatment in addition to usual care,
compared to usual care alone [25]. Herein,we provide in-depth analyses
of the temporal effects of CPAP on depression and anxiety among SAVE
participants, with the aim of defining subgroups of patients who may
derive the greatest benefit from treatment and the interaction of CPAP
treatment related effects on mood with improved sleepiness. We also
sought to quantify the relevance of these findings in the context of a sys-
tematic review of the randomised evidence to provide a robust estimate
of the effects of CPAP on depression and anxiety symptoms in patients
with OSA. We hypothesised that CPAP treatment would lead to reduc-
tions in both depression and anxiety symptoms overtime in OSA pa-
tients independent of improvements in daytime sleepiness.
2. Methods
2.1. Clinical trial design and participants
We conducted a secondary analysis of the SAVE studywhichwas an
international, multi-center, randomised, open, blinded-outcome
assessed, controlled trial of the effectiveness of CPAP for OSA for second-
ary prevention of CV disease, the details of which are outlined else-
where [25]. In brief, patients with a history of CV disease and
moderate to severe OSA (≥4% oxygen desaturation index, ≥12 events/
h [ApneaLink, ResMed]) during an overnight recording were recruited
from 89 clinical centres in seven countries between December 2008
and November 2013. Patients were excluded if they had severe oxygen
desaturation (b80% SpO2 for N10% of themonitoring time), severe day-
time sleepiness (Epworth Sleepiness Scale [ESS] score N 15), or predom-
inant central apnoea. Eligible participants were also required to have
used an average of at least 3 h per night of sham-CPAP during a one
week run-in period. The studywas approved by all relevant ethics com-
mittees, and written informed consent was obtained from eachparticipant or their appropriate surrogate. The study is registered at
ClinicalTrials.gov (NCT00738179).
2.2. Randomisation and interventions
Eligible patients were randomised centrally to receive either CPAP
therapy plus usual care (CPAP group) or usual care alone (usual-care
group). Randomisation was stratified by site, type of CV disease (car-
diac, cerebrovascular, or both), and severity of daytime sleepiness
(ESS score b 11 vs. ≥11). CPAP grouppatientswere providedwith an au-
tomated CPAP machine (REMstar Auto, M or PR series, Philips
Respironics) that was initially set in automatic mode for one week and
thereafter fixed to the 90th percentile of pressure that was calculated
by the automated positive airway pressure device from the recorded
data. The core sleep laboratory monitored CPAP adherence and all pa-
tients had guideline management of CV risk factors and were provided
advice on beneficial sleep habits and lifestyle changes to minimise
OSA symptoms.
2.3. Procedures and outcomes
Information on demographic and clinical characteristics, medical
history, medications, and health behaviours was recorded at the time
of enrolment. Anxiety and depression symptomswere assessed at base-
line, and at 6-, 24-, 48-, 72-, and 84-month visits (or end of study,
whichever came first), using the Hospital Anxiety and Depression
Scale (HADS). The HADS is a widely used screening tool for abnormal
mood, with subscales HADS-D andHADS-A each containing 7 items rel-
evant to depression and anxiety symptoms, respectively. HADS subscale
scores range from 0 to 21 and can be used to categorise mood as: 0–7
‘non-case’; 8–10 ‘possible case’; and 11–21 for ‘definite case’ of depres-
sion or anxiety [26,27]. For the main analyses, we defined depression
and anxiety ‘non-caseness’ as having a HADS score of 0–7; and
‘caseness’ as having a HADS score of 8–21, as a cut-off score of 8 was
found to be optimal for best sensitivity and specificity [26].
2.4. Statistical analysis
Baseline patient characteristics were summarised as mean (SD) for
continuous variables, and as number (%) for categorical variables, with
comparisons between groups made using Wilcoxon or chi-squared
tests. Unadjusted logistic regressionwas conducted to evaluate the rela-
tionship between CPAP and depression and anxiety caseness at the end
of follow-up, as defined by scores ≥ 8 on each of the HADS-D and HADS-
A subscales. Sensitivity analyses were performed with the higher cut-
point of ≥11 on each of the HADS-D and HADS-A [26]. We also adjusted
for the change from baseline to the end of study visit in the ESS score to
evaluatewhether any CPAP treatment effects on depression and anxiety
were independent of changes in sleepiness. Based on the changes in ab-
solute risk of depression and anxiety (HADS-D and HADS-A scores
8–21), we calculated the number needed to treat (NNT) at the end of
follow-up [28]. The impact of CPAP adherence on depression and anxi-
ety caseness was evaluated in patients randomised to CPAP treatment
using logistic regression adjusted for other confounders. CPAP adherent
was defined as having used ≥4 h (on average per night over a 48months
91D. Zheng et al. / EClinicalMedicine 11 (2019) 89–96period), which is a widely used cut-off in prior studies [8,29]. Heteroge-
neity in theCPAP treatment effect onHADS-D andHADS-Awas assessed
across subgroups defined by age (≤65 vs N65 years) sex, ethnicity
(Asian vs non-Asian), body mass index (BMI, b30 vs ≥30 kg/m2), base-
line depression and anxiety symptoms (HADS-D and HADS-A scores b8
vs ≥8, respectively), OSA severity (Apnoea Hypopnea Index [AHI] b30
vs ≥30 events/h), daytime sleepiness (ESS scores ≤10 vs N10), history
of coronary artery disease and cerebrovascular disease, through the ad-
dition of interaction terms to the logistic regression models. Longitudi-
nal changes in mean HADS-D and HADS-A scores by treatment group
were visually examined with trajectory plots, and the between-group
differences assessed using a linear mixed effects model with group,
time, and a group*time interaction asfixed effects; the overall difference
between groups in trajectories were assessed using the p-value for the
group*time interaction term. We also assessed temporal changes in
the individual components of the HADS using similar linear mixed ef-
fects models. All tests were two-sided and statistical significance set at
P b 0·05. Results are presentedwith 95% confidence intervals (CI). Anal-
yses were undertaken using SAS 9·0 (SAS Institute, Cary, NC, USA) and
STATA 14·2 (StataCorp, College Station, TX, USA).
2.5. Systematic review
The systematic review protocol was registered in PROSPERO
(CRD42017078483) in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) statement [30].
Inclusion criteriawere all randomised controlled trials with consecutive
patient recruitment, including parallel and crossover designs, compar-
ing CPAP to non-active controls (oral placebo, standard care, or sham-
CPAP) for mood improvement in adults (≥18 years and CPAP-naïve)
with clinically diagnosed OSA. The included trials required depressive
and/or anxiety symptoms measurement using validated question-
naires/clinical interviews that included the Beck's Depression Inventory
(BDI) [31], HADS [27], Montgomery-Åsberg Depression rating scale
(MADRS) [32], Profile of Mood States depression subscale [33], or the
Geriatric Depression Scale (GDS) [34]. Trials of patients with co-
morbid bipolar disorder, schizophrenia, or another psychiatric diagno-
sis, were excluded because of the potential to compromise CPAP adher-
ence, follow-up, and outcome assessments. Five databases were
searched: MEDLINE, EMBASE, PsychINFO, CINAHL and CENTRAL (from
inception to August 2018), using adapted versions of the outlined
Medline search strategy without language restrictions (Table 1, appen-
dix). Further literature was reviewed from reference lists of key clinical
trials and previous systematic reviews [6,8,9].
Article screening and data extractionwere conducted independently
by three authors (DZ, YX, SY) and discrepancies resolved in discussion.
Trials were included in the meta-analysis if they reported mean and
SD in depression and/or anxiety scores post-intervention in treatment
and control groups. We pooled standardised mean differences (andTable 1
Hospital Anxiety and Depression Scale (HADS) scores among patients with obstructive sleep a
CPAP
(Total n = 1220)
n (%)
Usual care
(Total n = 1190
n (%)
HADS-D†
Any depressive symptoms (score 8–21)‡ 221 (18·1) 295 (24·8)
Depression (score 11–21) 92 (7·5) 115 (9·7)
HADS-A†
Any anxiety symptoms (score 8–21)§ 176 (14·4) 202 (17·0)
Anxiety (score 11–21) 62 (5·1) 61 (5·1)
CI denotes confidence interval; CPAP, continuous positive airways pressure; HADS-D Hospital
Depression Scale – Anxiety subscale score; SD, standard deviation.
⁎ Logistic regression adjusted for change in Epworth Sleepiness Scale score from baseline to
† HADS-A and HADS-D scores range from 0 to 21, with higher scores indicating more severe
‡ Number needed to treat to prevent depression caseness (HADS-D score 8–21) for 3·7 year
§ Number needed to treat to prevent anxiety caseness (HADS-A score 8–21) for 3·7 years is95% CI) using random effects model of Dersimonian and Laird. Study
weights were generated using the inverse of the variance. Between-
study heterogeneity was assessed using the I2 statistic in combination
together with visual inspection of the forest plots. Subgroup analyses
by type of comparator (standard care, oral placebo, and sham-CPAP)
also were conducted. The risk of bias assessment was performed by
two independent reviewers (YX and XW) using the Cochrane risk of
bias assessment tool [35]. Funnel plots and Egger's test were used to as-
sess for publication bias. As the SAVE trial had the largest sample size
compared to all other studies, we performed meta-analyses excluding
the SAVE study as sensitivity analyses. Meta-analyses and publication
bias assessment were conducted using STATA 14·2 (StataCorp, College
Station, TX, USA) and risk of bias tables were produced using Revman
5·3 (Revman, The Cochrane Collaboration Oxford, UK).
3. Results
3.1. SAVE study
There were 2687 patients of the SAVE study who underwent
randomisation (1346 to CPAP intervention and 1341 to usual care
alone) and were followed for major CV outcomes for a mean of 3·7
(SD 1.6) years (Fig. 1). For the present analyses, we included 2410 par-
ticipants who had end of study mood assessment data. Patients in-
cluded in this study tended to be younger, with higher use of
antihypertensive and antithrombotic medication at baseline, and had
greater adherence to sham-CPAP during the screening phase of the
trial, compared to the 277 patients without end of study mood data
whowere excluded from these analyses (Table 2, Appendix). However,
the included patients were well balanced for characteristics between
CPAP treatment and usual care groups (Table 3, Appendix). At the end
of study follow-up, 221/1220 (18·1%) individuals in the CPAP group
and 295/1190 (24·8%) in the standard care group had ‘depression
caseness’ (HADS-D score ≥ 8) (Table 1). The unadjusted OR was 0·67
(95% CI 0·55–0·82; P b 0·0001), and the effect remained significant
after adjustment for the change in ESS scores during follow-up (ad-
justed OR 0·80, 95% CI 0·65–0·98; P = 0·031). In longitudinal analysis
of the HADS-D, there was an overall reduction in depressive symptoms
(p b 0·0001 for group*time interaction) and significantly fewer subjects
with ‘depression caseness’ at most follow-up visits in the CPAP group;
the treatment effect being apparent at 6 months post-randomisation
(Fig. 1, Table 4, Appendix). Depression caseness with a higher cut-
point score ≥ 11 on the HADS-D was also lower in the CPAP compared
to usual care group, but the effect was not significant due to small pa-
tient numbers (Table 1). The number needed to treat (NNT) in order
to prevent one case of depression was 15 (95% CI 10–31). There ap-
peared to be no significant effect of CPAP adherence on depression
and anxiety (Table 5, appendix). Subgroup analyses showed that pa-
tientswith pre-existing depression symptomshad significantly reducedpnoea and cardiovascular disease at the end of follow-up in the SAVE trial (n = 2410).
)
Crude OR (95%CI) P-value Adjusted OR⁎
(95% CI)
P-value
0·67 (0·55–0·82) b0·0001 0·80 (0·65–0·98) 0·031
0·76 (0·57–1·02) 0·064 0·96 (0·71–1·30) 0·80
0·83 (0·66–1·03) 0·086 0·98 (0·78–1·24) 0·89
0·99 (0·69–1·42) 0·96 1·24 (0·84–1·81) 0·28
Anxiety and Depression Scale - Depression subscale score; HADS-A Hospital Anxiety and
end of study.
symptoms.
s is 15 (95% confidence interval 10 to 31).
39 (95% confidence interval 18 to −281).
Fig. 1. Consort flow diagram CPAP denotes continuous positive airways pressure; OSA, obstructive sleep apnoea.
92 D. Zheng et al. / EClinicalMedicine 11 (2019) 89–96depression symptomswith CPAP treatment (Table 6, appendix). Analy-
ses of each of the questions on theHADS-D showed a consistent effect of
CPAP treatment across individual symptom components (Fig. 2, appen-
dix). Anxiety caseness (defined by HADS-A scores ≥ 8) was non-
significantly lower in the CPAP group (176/1220, 14·4%) compared to
usual care group (202/1190, 17·0%) (Table 1). A trajectory plot of anx-
iety symptoms (HADS-A score) showed small reductions in anxiety in
both usual care and CPAP groups over time, being slightly greater in
those assigned to CPAP (Fig. 3, Table 4, appendix). Analyses of the indi-
vidual questions on the HADS showed that CPAP treatment reduced
four individual components of the HADS-A (Fig. 4, appendix).
3.2. Systematic review and meta-analysis
Our systematic search identified 1624 articles, with full text review
identifying 20 eligible studies (4255 participants) that evaluated
changes in depression and/or anxiety symptoms in response to CPAP
in OSA patients (Table 7, Fig. 5, Appendix). All 20 included trials re-
ported on depression symptoms for CPAP, although only 17 (4057 par-
ticipants) had the necessary numerical data for inclusion in a meta-
analysis. The overall standardisedmean difference for depression symp-
toms for CPAP versus control was −0·18 (95%CI -0·24 to −0·12)
(Fig. 2). We identified 13 trials with outcomes related to anxiety symp-
toms for quantitative synthesis: the overall standardised mean differ-
ence for anxiety symptoms for CPAP versus control was −0·07
(−0·17 to 0·04) (Fig. 3). In subgroup meta-analysis stratified by the
type of control group used, CPAP was superior to both standard care
and oral placebo for depression symptoms, while anxiety symptomswere alleviated with CPAP only when compared to standard care. By
contrast, there was no effect of CPAP treatment when compared to
sham-CPAP treatment for either depression (Fig. 2) or anxiety (Fig. 3).
Sensitivity analyses excluding the SAVE trial from meta-analyses
showed similar results to the main analyses (Figs. 6–7, Appendix). The
included trials were mostly of high quality (Fig. 8, Appendix) and
there was low between-study heterogeneity (I2 values 0% and 23·6%
for depression and anxiety studies respectively). Therewas no evidence
of publication bias (Figs. 9–10 Appendix).
4. Discussion
Mood disorders are common in patients at high risk of CV disease,
and depression in particular is associated with premature mortality
and recurrent CV events [36,37]. In the SAVE study of 2687 patients
with established CV disease and OSA who were followed over several
years, CPAP was found to significantly reduce the rates of clinically sig-
nificant ‘caseness’ of depression but not of anxiety. The effect of CPAP
occurred within several months of commencing the treatment, inde-
pendently of improvements in daytime sleepiness, and was greater in
those with pre-existing depression. Taken together with a systematic
reviewof 20 randomised controlled studies, these results support a ben-
eficial effect of CPAP treatment for the alleviation of depression
symptoms.
The relationship between sleep disturbance and abnormal mood is
strong and bidirectional [38,39]. InOSA patients, there are a range of rel-
evant pathophysiological mechanisms operating that include apnoea-
induced sleep fragmentation, hypoxia, and daytime sleepiness, cerebral
Fig. 2.Meta-analysis of the effect of CPAP for depression symptoms Pooled standardisedmean difference (SMD)was calculated using a random effectsmodel. Boxes are SMD and lines are
95% confidence interval (CI). The vertical solid line represents no difference between CPAP and control. Values to the left of the solid line favour CPAP benefit. Pooled SMDs and 95%CI are
represented by the diamond shapes.
93D. Zheng et al. / EClinicalMedicine 11 (2019) 89–96grey matter structural changes, and metabolic abnormalities, which
may be reversed by CPAP treatment [3,40–44]. This study defines a
clear effect of CPAP treatment on depressive symptoms which actsFig. 3.Meta-analysis of the effect of CPAP for anxiety symptomsPooled standardisedmean differ
confidence interval (CI). The vertical solid line represents no difference between CPAP and co
represented by diamond shapes.independently of improvements in daytime sleepiness. Although analy-
sis of depression symptoms as a continuous variable did not show any
difference between CPAP and usual care groups at 72months timepoint,ence (SMD)was calculated using a randomeffectsmodel. Boxes are SMDand lines are 95%
ntrol. Values to the left of the solid line favour CPAP benefit. Pooled SMD and 95%CI are
94 D. Zheng et al. / EClinicalMedicine 11 (2019) 89–96this is likely due to small numbers of patients at this stage of the study. A
detailed analysis of the individual components of the HADS-D also
showed a consistent effect of CPAP treatment across all of the questions
including those related to sleepiness, such as “feeling sloweddown” and
anhedonia-oriented symptoms. These effects remained after adjust-
ment for the change in sleepiness (ESS) during follow-up. Sub-group
analysis of the SAVE study also showed a greater effect of CPAP in
those with prior depression, which is consistent with a prior systematic
review [8]. As the NNT (i.e. 15) for CPAP to prevent depression is com-
parable to remission rates achieved for some established antidepressant
drugs [45], our findings provide further support for the broader benefi-
cial effects of CPAP in those with OSA, and especially those at high CV
risk, where there is the potential for enhanced mood to improve long-
term CV outcomes [29,45].
Although improvements were observed in four (out of seven) indi-
vidual components of the HADS-A subscale, the rate of anxiety caseness
was not significantly lower among the CPAP treated patients at the end
of study. The lack of significant difference in rates of anxiety caseness
between the groups may be largely due to parallel improvements in
symptoms in the usual care group, although an anxiety inducing effect
of CPAP from, for example, from the mask application, may also be rel-
evant. Another issue is a steady reduction in anxiety symptoms in
both groupswhichmight arise as a result of repeated testing and regular
interactions with health care workers (i.e. the Hawthorne effect) [24].
Our systematic review and meta-analysis confirmed the efficacy of
CPAP in reducing depression but not anxiety symptoms. The overall
neutral effect of CPAP treatment on anxiety symptoms may be due to
a slight positive, albeit non-significant effect of sham-CPAP as compared
to therapeutic CPAP in several included trials. The reduction in depres-
sion symptoms from CPAP occurred when compared to placebo pill or
usual care, but not when compared with sham-CPAP. Sham-CPAP is de-
signed to provide flow of air via a facemask at very low sub-therapeutic
pressure; the mask and pump being identical in appearance to true
CPAP, with the exception that the mask has a larger hole for venting
air. The use of sham-CPAP as a true control in CPAP studies has been
controversial, and earlier studies have found small improvements in
sleep and respiratory parameters as a result of its use [46–48]. A study
on sham-CPAP reported small changes in OSA patients toward worse
quality sleep but a reduced severity of sleep disordered breathing (com-
plete airway obstruction [apneas] tending to be replaced by partial ob-
struction events [hypopneas]) and a reduced overnight burden of
hypoxia [48]. It is possible, therefore, that sham-CPAP may obscure
some of the effects of CPAP on depression and anxiety symptoms [49],
and further research is warranted to better define the effects of sham-
CPAP on mood.
Key strengths of these analyses are that they were derived from the
SAVE study, the largest randomised evaluation of the effects of CPAP for
OSA in CV patients who were well characterised and followed up in a
range of clinical settings, thus providing high validity and
generalisability of the findings. Moreover, the SAVE study allowed an
evaluation of treatment effects on depression and anxiety symptoms
over a substantially longer time period than has previously been under-
taken, and incorporation of these data into a systematic review of other
trials provided reliability and consistency of findings. However, there
are some limitations, particularly in the use of screening tools to assess
mood outcomes as opposed to gold standard, semi-structured, psychiat-
ric interviews. Even so, self-reported depression and anxiety scores are
more relevant to routine clinical practice (easy to administer, low cost),
and are highly correlated with clinical diagnoses of depression and anx-
iety [26,50]. Although we used recommended cut-point scores of eight
on both HADS-A and HADS-D subscales to provide an optimum balance
of sensitivity and specificity for abnormal mood in studies [26], screen-
ing instruments are prone to misdiagnosis and clinical uncertainty re-
garding appropriate clinical pathways for care. Another limitation is
that we lacked information on psychotropic medicines whichmay con-
found the results, although patients with major mental illness wouldlikely have avoided participating in such studies. Moreover, as we only
included patientswith coexistingmoderate–severe OSA and CVdisease,
our results may not be generalisable to patients with mild OSA or
broader OSA population without CV disease. For the systematic review,
there are clear limitations to the various component trials, including the
lack of blinding of patients or their outcome assessors, short duration of
follow-up, and variable adherence to CPAP. Finally, a few studies were
excluded due to a lack of numerical data for statistical synthesis [18,
22,51].
5. Conclusion
In summary, our detailed analysis of the SAVE study has shown that
CPAP for moderate–severe OSA in patients with CV disease has broader
benefits in terms of preventing depression caseness, independent of im-
proved sleepiness. Our additional systematic review provides further
support of the treatment effect of CPAP for depression, but not for anx-
iety symptoms.
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